Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: A multi-institutional study

Journal of Infection and Chemotherapy

Volumn 17, Issue 1, 2011, Pages 58-67

  Nakagawa, Yasunori ^a   Suzuki, Kenshi ^a   Hirose, Takayuki ^b   Chou, Takaaki ^b   Fujisawa, Shin ^c   Kida, Michiko ^d   Usuki, Kensuke ^d   Ishida, Yoji ^e   Taniguchi, Shuichi ^f   Kouzai, Yasuji ^g   Tomoyasu, Shigeru ^h   Miyazaki, Koji ⁱ   Higashihara, Masaaki ⁱ   Ando, Kiyoshi ^j   Aoki, Sadao ^k   Arai, Ayako ^p   Akiyama, Nobu ^q   Hatake, Kiyohiko ^l   Okamoto, Shinichiro ^m   Dan, Kazuo ⁿ   Ohyashiki, Kazuma ^o   Urabe, Akio ^d   more..

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^h SHOWA UNIVERSITY   (Japan)

ⁱ KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j TOKAI UNIVERSITY   (Japan)

^k NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^l CANCER INSTITUTE HOSPITAL   (Japan)

^m KEIO UNIVERSITY   (Japan)

ⁿ NIPPON MEDICAL SCHOOL   (Japan)

^o TOKYO MEDICAL UNIVERSITY   (Japan)

^p TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^q TEIKYO UNIVERSITY   (Japan)

more..

Author keywords

Biapenem; Febrile neutropenia; Hematopoietic diseases

Indexed keywords

BIAPENEM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; BLOOD DISEASE; BODY TEMPERATURE MEASUREMENT; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; NONHUMAN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PATIENT ASSESSMENT; RASH;

EID: 79951554132     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0075-3     Document Type: Article

References (23)

1. WT Hughes D Armstrong GP Bodey R Feld GL Mandell JD Meyers From the Infectious Diseases Society of America, et al. 1990 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever J Infect Dis 161 381 396 1:STN:280:DyaK3c7osl2ntQ%3D%3D 2179420 (Pubitemid 20107933)
2. WT Hughes D Armstrong GP Bodey AE Brown JE Edwards R Feld, et al. 1997 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America Clin Infect Dis 25 551 573 1:STN:280:DyaK2svlvVWisQ%3D%3D 10.1086/513764 9314442 (Pubitemid 127774275)
3. WT Hughes D Armstrong GP Bodey EJ Bow AE Brown T Calandra, et al. 2002 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 730 751 10.1086/339215 11850858 (Pubitemid 34194843)
4. T Masaoka 1998 Conclusions and recommendations: evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan Int J Hematol 68 S39
5. M Hikida K Kawashima M Yoshida S Mitsuhashi 1992 Inactivation of new carbapenem antibiotics by dehydropeptidase-1 from porcine and human renal cortex J Antimicrob Chemother 30 129 134 1:CAS:528:DyaK38XmtVCntLc%3D 10.1093/jac/30.2.129 1301069
6. Sakai H, Sanada M, Shimamoto K, Azuma R, Harada H, Mori H, et al. Clinical evaluation of biapenem for febrile neutropenia in patients with hematological disorders. Jpn J Antibiot. 2007;60:125-31 (Japanese). (Pubitemid 46933143)
7. Kasahara S, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, et al. Clinical effects of biapenem on febrile neutropenia in patients with hematological malignancy. Jpn J Antibiot. 2008;61:115-21 (Japanese).
8. Sasada M. Anti-infection measures. Nippon Rinsho. 2007;65:S445-9 (Japanese).
9. Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Uehara N, Yasujima M, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn J Antibiot. 2007;60:344-77 (Japanese). (Pubitemid 351154892)
10. Matsumoto F, Inoue M, Sakurai I, Ishida Y, Osonoi T, Itoh H, et al. A comparative study of biapenem and imipenem/cilastatin in lower respiratory infections. Jpn J Chemother. 2000;48:45-67 (Japanese). (Pubitemid 30095564)
11. Shibata H, Yamane T, Sakamoto E, Nakamae H, Ohta K, Hino M. Clinical analysis of antibiotic treatment for febrile neutropenia. Jpn J Antibiot. 2005;58:382-7 (Japanese). (Pubitemid 41355455)
12. Urabe A, Mutoh Y, Mizoguchi H, Toyama K, Oshimi K, Suzuki K, et al. Efficacy and safety of panipenem/betamipron (PAPM/BP) in the treatment of infections accompanying hematologic diseases. Antibiot Chemother. 1998;14:119-26 (Japanese).
13. Sawae Y, Niho Y, Okamura T, Gondo H, Suehiro Y, Kumakawa M, et al. Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders. Jpn J Antibiot. 1996;49:1049-61 (Japanese). (Pubitemid 27043181)
14. GP Bodey V Rodriguez HY Chang G Narboni 1978 Fever and infection in leukemic patients: a study of 494 consecutive patients Cancer 41 1610 1622 1:STN:280:DyaE1c7ks1aruw%3D%3D 10.1002/1097-0142(197804)41:4<1610::AID- CNCR2820410452>3.0.CO;2-B 346201 (Pubitemid 8333322)
15. WA Craig 1995 Interrelationship between pharmacokinetic and pharmacodynamic in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 89 96 1:CAS:528:DyaK2MXntlGqurk%3D 10.1016/0732-8893(95)00053-D 7587056
16. WA Craig 1998 Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1 12 1:CAS:528:DyaK1cXltVaqtw%3D%3D 10.1086/516284 9455502 (Pubitemid 28068148)
17. WA Craig 2002 The role of pharmacodynamics in effective treatment of community-acquired pathogens Adv Stud Med 2 126 134
18. GL Drusano 2003 Prevention of resistance: a goal for dose selection for antimicrobial agents Clin Infect Dis 36 S42 S50 1:CAS:528:DC%2BD3sXht1ynu7o%3D 10.1086/344653 12516029 (Pubitemid 36140468)
19. T Takata K Aizawa A Shimizu S Sakakibara H Watabe K Totsuka 2004 Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis J Infect Chemother 10 76 85 1:CAS:528: DC%2BD2cXktlahu7k%3D 10.1007/s10156-003-0292-0 15160299 (Pubitemid 38590729)
20. K Tamura H Matsuoka J Tsukada M Masuda S Ikeda E Matsuishi, et al. 2002 Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study Am J Hematol 71 248 255 1:CAS:528:DC%2BD38Xps1Ortr8%3D 10.1002/ajh.10236 12447952 (Pubitemid 35396940)
21. K Tamura K Imajo N Akiyama K Suzuki A Urabe K Ohyashiki, et al. 2004 Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia Clin Infect Dis 39 S15 S24 1:CAS:528:DC%2BD2cXntVahs78%3D 10.1086/383046 15250016 (Pubitemid 38971471)
22. J Klastersky 1997 Treatment of neutropenic infection: trends towards monotherapy? Support Care Cancer 5 365 370 1:STN:280:DyaK2svmtlGltQ%3D%3D 10.1007/s005200050093 9322347 (Pubitemid 27402588)
23. R Ramphal 2004 Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens Clin Infect Dis 39 S25 S31 10.1086/383048 15250017 (Pubitemid 38971472)